News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Supply readiness follows months of manufacturing to ensure timely and ample supply
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Subscribe To Our Newsletter & Stay Updated
